Patents by Inventor Sherri L. Mudri

Sherri L. Mudri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of using IL-31 to treat chronic obstructive pulmonary disease (COPD)
    Patent number: 8298524
    Abstract: Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proinflammatory cytokines and include administration of the IL-31 agonist during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.
    Type: Grant
    Filed: August 23, 2011
    Date of Patent: October 30, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Janine M. Bilsborough, Eric M. Chadwick, Sherri L. Mudri
  • METHODS OF USING IL-31 TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
    Publication number: 20120083456
    Abstract: Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proinflammatory cytokines and include administration of the IL-31 agonist during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.
    Type: Application
    Filed: August 23, 2011
    Publication date: April 5, 2012
    Inventors: Janine M. Bilsborough, Eric M. Chadwick, Sherri L. Mudri
  • Methods of determining dose of IL-31 agonist to treat pulmonary inflammation
    Patent number: 8029775
    Abstract: Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proinflammatory cytokines and include administration of the IL-31 agonist during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.
    Type: Grant
    Filed: August 26, 2010
    Date of Patent: October 4, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Janine M. Bilsborough, Eric M. Chadwick, Sherri L. Mudri
  • METHODS OF DETERMINING DOSE OF IL-31 AGONIST TO TREAT PULMONARY INFLAMMATION
    Publication number: 20110008820
    Abstract: Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proinflammatory cytokines and include administration of the IL-31 agonist during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.
    Type: Application
    Filed: August 26, 2010
    Publication date: January 13, 2011
    Inventors: JANINE M. BILSBOROUGH, ERIC M. CHADWICK, SHERRI L. MUDRI
  • Methods of using IL-31 to treat airway hyper-responsiveness and asthma
    Patent number: 7799323
    Abstract: Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proimflammatory cytokines and include administration of the IL-31 agonsit during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.
    Type: Grant
    Filed: January 10, 2008
    Date of Patent: September 21, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Janine M. Bilsborough, Eric M. Chadwick, Sherri L. Mudri
  • METHODS OF USING IL-31 TO TREAT AIRWAY HYPER-RESPONSIVENESS AND ASTHMA
    Publication number: 20080260686
    Abstract: Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proimflammatory cytokines and include administration of the IL-31 agonsit during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.
    Type: Application
    Filed: January 10, 2008
    Publication date: October 23, 2008
    Inventors: Janine M. Bilsborough, Eric M. Chadwick, Sherri L. Mudri, Yue Yao, Hongping Ren, Jane A. Gross
  • Hexokinase promoter and assay method
    Patent number: 5741704
    Abstract: Isolated DNA molecules comprising a portion of a human hexokinase gene promoter are disclosed. The molecules comprise promoter and insulin-sensitive transcription regulatory elements. These molecules can be used within methods for detecting insulin-like activity in test substances.
    Type: Grant
    Filed: December 28, 1995
    Date of Patent: April 21, 1998
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Sherri L. Mudri